Louise Frederika Kooij sold $5.2M of NAMS
Chief Accounting Officer at NewAmsterdam Pharma Co N.V.. 145,000 shares at an average of $35.84, traded Dec 23, 2025, filed Dec 29, 2025.
Score components
- +15RoleOfficer
- +25Trade size$5.2M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-335513, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 23, 2025 | MOption exercise Ordinary Shares10b5-1 | +75,117 | $10.00 | $751k | 90,117 | Dec 29, 2025 |
| Dec 23, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -75,117 | $36.21 | $2.7M | 15,000 | Dec 29, 2025 |
| Dec 24, 2025 | MOption exercise Ordinary Shares10b5-1 | +26,011 | $10.00 | $260k | 41,011 | Dec 29, 2025 |
| Dec 24, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -26,011 | $35.68 | $928k | 15,000 | Dec 29, 2025 |
| Dec 26, 2025 | MOption exercise Ordinary Shares10b5-1 | +38,872 | $10.00 | $389k | 53,872 | Dec 29, 2025 |
| Dec 26, 2025 | MOption exercise Ordinary Shares10b5-1 | +5,000 | $10.90 | $55k | 58,872 | Dec 29, 2025 |
| Dec 26, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -43,872 | $35.30 | $1.5M | 15,000 | Dec 29, 2025 |
| Dec 23, 2025 | MOption exercise Option (right to buy)derivative10b5-1 | -75,117 | $0.00 | $0 | 204,898 | Dec 29, 2025 |
| Dec 24, 2025 | MOption exercise Option (right to buy)derivative10b5-1 | -26,011 | $0.00 | $0 | 178,887 | Dec 29, 2025 |
| Dec 26, 2025 | MOption exercise Option (right to buy)derivative10b5-1 | -38,872 | $0.00 | $0 | 140,015 | Dec 29, 2025 |
| Dec 26, 2025 | MOption exercise Option (right to buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 218,134 | Dec 29, 2025 |
Related signals
Other insiders at NewAmsterdam Pharma Co N.V. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $1.3M 50,246 shares | -42% | |
| 38Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | Michael H. Davidson Chief Executive Officer | $227k 10,000 shares | +1% | |
| 26Weak | NAMSsell NewAmsterdam Pharma Co N.V. | John W Smither director | $41k 1,600 shares | -15% | |
| 75Notable | NewAmsterdam Pharma Co N.V. | Louis G Lange director | $1.4M 44,619 shares | -81% | |
| 73Notable | NewAmsterdam Pharma Co N.V. | Louis G Lange director | $829k 28,186 shares | -100% | |
| 40Moderate | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $9.1M 300,000 shares | -173% | |
| 70Notable | NewAmsterdam Pharma Co N.V. | Michael H. Davidson Chief Executive Officer | $15M 443,707 shares | -72% | |
| 50Moderate | NewAmsterdam Pharma Co N.V. | Michael H. Davidson Chief Executive Officer | $11M 306,293 shares | -58% | |
| 65Notable | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $1.6M 45,481 shares | -46% | |
| 33Weak | NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $2.3M 72,428 shares | -113% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.